Table 2.
Association between patient, tumor features and response to radiotherapy, 3 months after completion
| Features | Responders | non-responders | Value - p |
|---|---|---|---|
| (n = 92) | (n = 35) | ||
| Median Age, years (SD) | 47.5 (11.9) | 49.9 (12.6) | 0.17 |
| Median Tumor size, cm (SD) | 6.4 (2.0) | 6.7 (2.1) | 0.58 |
| FIGO staging, number of patients (%) | 0.26* | ||
| IIB | 36 (78.3) | 10 (21.7) | |
| IIIB | 56 (69.1) | 25 (30.9) | |
| Differentiation degree, number of patients (%) | |||
| Well | 7 (77.8) | 2 (22.2) | 0.62* |
| Moderetaly | 65 (75.6) | 21 (24.4) | |
| Poorly | 11 (64.7) | 6 (35.3) | |
| Treatment type, number of patients (%) | 0.21* | ||
| Exclusive EBRT + Brachytherapy | 36 (66.7) | 18 (33.3) | |
| Chemo-Radiotherapy + Brachytherapy | 56 (76.7) | 17 (23.3) | |
| Protein Expression, number of patients (%) | |||
| CAIX | |||
| Negative | 63 (70) | 27 (30) | 0.02**₤ |
| Positive | 19(95) | 1 (5) | |
| HIF1 α | |||
| Negative | 27 (81.8) | 6 (18.2) | 0.14*₤ |
| Positive | 63 (68.4) | 29 (31.6) | |
| GLUT1 | |||
| Negative | 52 (72.2) | 20 (27.8) | 0.44*₤ |
| Positive | 30 (78.9) | 8 (21.1) | |
| IGF1R α | |||
| Negative | 17 (65.3) | 9 (34.7) | 0.39*₤ |
| Positive | 73 (73.7) | 26 (26.3) | |
| IGF1R β | |||
| Negative | 22 (75.8) | 7 (24.2) | 0.59*₤ |
| Positive | 68 (70.9) | 28 (29.1) | |
| Survivin | |||
| Negative | 11 (78.6) | 3 (21.4) | 0.67*₤ |
| Positive | 74 (73.3) | 27 (26.7) | |
| Impact of anemia, number of patients (%) | |||
| Hb > 11 g/dl | 71 (78) | 20 (21.9) | 0.02* |
| Hb ≤ 11 g/dl | 21 (58.3) | 15 (41.6) | |
SD: standard deviation, FIGO: International Federation of Gynecology and Obstetrics, EBRT: external beam radiotherapy
*Chi2 test
**Exact fisher test
₤Type I error is set to 0.0085 in order to correct for multiple testing, based on the Dunn-Sidak’s method